![Jean-Philippe Tripet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Philippe Tripet
Fondateur chez
Aravis AG
Profil
Jean-Philippe Tripet is the founder and currently holds the position of Chairman at Aravis AG, which was founded in 2001.
He is also currently a Director at the University of Cambridge, Evolva SA, and Fondation Fournier Majoie pour l'Innovation EtUtPub.
In his former positions, Mr. Tripet served as Chairman at MerLion Pharmaceuticals Pte Ltd., Vice Chairman at Evolva Holding SA, Director at Omeros Corp., Nura, Inc., Borean Pharma ApS, ESBATech AG, Combinature BioPharm AG, Athelas SA, S*BIO Pte Ltd., and Telormedix SA. He also held the position of Vice President-Equity Research at Union Bank of Switzerland and Senior Executive Vice President at Banque Lombard Odier & Cie SA (Investment Management).
Additionally, he was a Member of the Management Board at Synosia Therapeutics AG and Symetis SA, and an Analyst at Lombard Odier Darier Hentsch & Cie (Equity Brokerage).
Mr. Tripet completed his undergraduate studies and obtained an MBA from the University of Geneva.
Postes actifs de Jean-Philippe Tripet
| Sociétés | Poste | Début |
|---|---|---|
Aravis AG
 Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Fondateur | 28/06/2001 |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | - |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotech company focused on the research, development and commercialization of ingredients based on nature | Corporate Officer/Principal | 18/11/2009 |
Fondation Fournier Majoie pour l'Innovation EtUtPub
 Fondation Fournier Majoie pour l'Innovation EtUtPub Miscellaneous Commercial ServicesCommercial Services Provides social services | Directeur/Membre du Conseil | 15/12/2009 |
Anciens postes connus de Jean-Philippe Tripet
| Sociétés | Poste | Fin |
|---|---|---|
| EVONEXT HOLDINGS SA | Directeur/Membre du Conseil | 09/05/2012 |
| OMEROS CORPORATION | Directeur/Membre du Conseil | 30/06/2011 |
Nura, Inc.
 Nura, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops pharmaceutical products | Directeur/Membre du Conseil | 01/08/2006 |
Lombard Odier Darier Hentsch & Cie (Equity Brokerage)
 Lombard Odier Darier Hentsch & Cie (Equity Brokerage) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 12/02/1997 |
Banque Lombard Odier & Cie SA (Investment Management)
 Banque Lombard Odier & Cie SA (Investment Management) Investment ManagersFinance Lombard Odier-IM is an active, research-driven manager which focuses on long-term capital preservation and tailoring their services to their clients' profiles. The firm shares research globally and combines a top-down view with a bottom-up security selection process. Their investment strategy team elaborates and continuously updates macroeconomic forecasts and investment scenarios based on quantitative and technical analysis, resulting in geographical, sectoral and currency allocations. The buy side equity research team tracks a predefined universe of companies worldwide, with a focus on the Swiss market. They also identify promising sectors, regions and themes, assisted by the quantitative research team. | Corporate Officer/Principal | - |
Formation de Jean-Philippe Tripet
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
82
Relations au 1er degré
20
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 20 |
|---|---|
Union Bank of Switzerland
 Union Bank of Switzerland Major BanksFinance Provides banking services | Finance |
Banque Lombard Odier & Cie SA (Investment Management)
Banque Lombard Odier & Cie SA (Investment Management) Investment ManagersFinance Lombard Odier-IM is an active, research-driven manager which focuses on long-term capital preservation and tailoring their services to their clients' profiles. The firm shares research globally and combines a top-down view with a bottom-up security selection process. Their investment strategy team elaborates and continuously updates macroeconomic forecasts and investment scenarios based on quantitative and technical analysis, resulting in geographical, sectoral and currency allocations. The buy side equity research team tracks a predefined universe of companies worldwide, with a focus on the Swiss market. They also identify promising sectors, regions and themes, assisted by the quantitative research team. | Finance |
Omeros Corp.
 Omeros Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes small-molecule & protein therapeutics | Health Technology |
Nura, Inc.
Nura, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops pharmaceutical products | Health Technology |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of psychiatry and neurology diseases | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Borean Pharma ApS
 Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals drugs and protein engineering services | Health Technology |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services Develops antibody fragment therapeutics | Commercial Services |
Combinature BioPharm AG
 Combinature BioPharm AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops drugs | Commercial Services |
University of Geneva
 University of Geneva Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aravis AG
Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Finance |
Symetis SA
 Symetis SA BiotechnologyHealth Technology Develops products for pediatric cardio-vascular applications | Health Technology |
Lombard Odier Darier Hentsch & Cie (Equity Brokerage)
Lombard Odier Darier Hentsch & Cie (Equity Brokerage) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Athelas SA
 Athelas SA Miscellaneous Commercial ServicesCommercial Services Researches and develops bacterial inhibitors of pathogenicity against relevant human pathogens for the purpose of fighting bacterial infectious diseases | Commercial Services |
MerLion Pharmaceuticals Pte Ltd.
 MerLion Pharmaceuticals Pte Ltd. Pharmaceuticals: MajorHealth Technology Develops novel antibiotics | Health Technology |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers novel targeted small molecule drugs | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotech company focused on the research, development and commercialization of ingredients based on nature | Commercial Services |
Telormedix SA
 Telormedix SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases | Health Technology |
Evolva Holding SA
 Evolva Holding SA Food: Specialty/CandyConsumer Non-Durables Develops and sells flavors, fragrances and health ingredients | Consumer Non-Durables |
Fondation Fournier Majoie pour l'Innovation EtUtPub
Fondation Fournier Majoie pour l'Innovation EtUtPub Miscellaneous Commercial ServicesCommercial Services Provides social services | Commercial Services |
